Ebola 2018 – Implications for travel health advice and relevance for travel medicine

Grobusch, Martin P.; Schaumburg, Frieder; Weitzel, Thomas; Rothe, Camilla; Hänscheid, Thomas; Goorhuis, Abraham

doi:10.1016/j.tmaid.2018.06.009

Cited by 3 publications

(1 citation statement)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The virus can be contracted via blood, secretions, organs and other bodily fluids of infected people, and is transmitted by wild animals such as fruits bats, porcupines and non-human primates. The risk of infection for travelers is low as most infections occur in remote areas in sub-Saharan Africa; although during the 2014–2016 Western African EVD outbreak, there was a serious threat for people traveling to endemic areas (especially for health care workers) to get exposed to the virus [ 46 ]. There are currently two licensed vaccines by the EMA and FDA, the rVSV-ZEBOV (Ervebo®) and Ad26.ZEBOV/MVA-BN-Filo (Zabdeno®/Mavbea®), which both only targets the (Z)EBOV (or Zaire ebolavirus ), while the most recent outbreak in Uganda was caused by the Sudan strain (Sudan virus or SUDV) [ 47 ].…”

Section: Literature Review On the Development Of Monoclonal Antibodie...mentioning

confidence: 99%

Monoclonal antibody applications in travel medicine

de Jong,

Grobusch

2024

Trop Dis Travel Med Vaccines

Self Cite

View full text Add to dashboard Cite

For decades, immunoglobulin preparations have been used to prevent or treat infectious diseases. Since only a few years, monoclonal antibody applications (mAbs) are taking flight and are increasingly dominating this field. In 2014, only two mAbs were registered; end of October 2023, more than ten mAbs are registered or have been granted emergency use authorization, and many more are in (pre)clinical phases. Especially the COVID-19 pandemic has generated this surge in licensed monoclonal antibodies, although multiple phase 1 studies were already underway in 2019 for other infectious diseases such as malaria and yellow fever. Monoclonal antibodies could function as prophylaxis (i.e., for the prevention of malaria), or could be used to treat (tropical) infections (i.e., rabies, dengue fever, yellow fever). This review focuses on the discussion of the prospects of, and obstacles for, using mAbs in the prevention and treatment of (tropical) infectious diseases seen in the returning traveler; and provides an update on the mAbs currently being developed for infectious diseases, which could potentially be of interest for travelers.

show abstract

Section: Literature Review On the Development Of Monoclonal Antibodie...mentioning

confidence: 99%

Monoclonal antibody applications in travel medicine

de Jong,

Grobusch

2024

Trop Dis Travel Med Vaccines

Self Cite

View full text Add to dashboard Cite

show abstract

Ebola and guidance for those who travel or migrate in endemic areas

Balikuddembe

2020

Travel Medicine and Infectious Disease

View full text Add to dashboard Cite

Aetiology of fever in returning travellers and migrants: a systematic review and meta-analysis

Buss

Genton

D’Acremont

2020

Journal of Travel Medicine

View full text Add to dashboard Cite

Background Numerous publications focus on fever in returning travelers, but there is no known systematic review considering all diseases, or all tropical diseases causing fever. Such a review is necessary in order to develop appropriate practice guidelines. Objectives Primary objectives of this review were i) to determine the etiology of fever in travelers/migrants returning from (sub) tropical countries as well as the proportion of patients with specific diagnoses, and ii) to assess the predictors for specific tropical diseases. Method Embase, MEDLINE and Cochrane Library were searched with terms combining fever AND travel/migrants. All studies focusing on causes of fever in returning travelers and/or clinical and laboratory predictors of tropical diseases were included. Meta-analyses were performed on frequencies of etiological diagnoses. Results 10064 studies were identified; 541 underwent full-text review; 30 met criteria for data extraction. Tropical infections accounted for 33% of fever diagnoses, with malaria causing 22%, dengue 5% and enteric fever 2%. Non-tropical infections accounted for 36% of febrile cases, with acute gastroenteritis causing 14% and respiratory tract infections 13%. Positive likelihood ratios demonstrated that splenomegaly, thrombocytopenia and hyperbilirubinemia were respectively 5–14, 3–11 and 5–7 times more likely in malaria than non-malaria patients. High variability of results between studies reflects heterogeneity in study design, regions visited, participants’ characteristics, setting, laboratory investigations performed, and diseases included. Conclusion Malaria accounted for one fifth of febrile cases, highlighting the importance of rapid malaria testing in febrile returning travelers, followed by other rapid tests for common tropical diseases. High variability between studies highlights the need to harmonize study designs and to promote multi-center studies investigating predictors of diseases, including of lower incidence, which may help to develop evidence-based guidelines. The use of clinical decision support algorithms by health workers which incorporate clinical predictors, could help standardize studies as well as improve quality of recommendations.

show abstract

Ebola 2018 – Implications for travel health advice and relevance for travel medicine

Cited by 3 publications

References 6 publications

Monoclonal antibody applications in travel medicine

Monoclonal antibody applications in travel medicine

Ebola and guidance for those who travel or migrate in endemic areas

Aetiology of fever in returning travellers and migrants: a systematic review and meta-analysis

Contact Info

Product

Resources

About